Eylea 1
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Eylea 1 in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Eylea 1.
45
Global Revenue Ranking
Recent articles on PMLiVE featuring Eylea 1
The rare eye disease often impacts infants who are born before 31 weeks of pregnancy
The data showed, after two years, that 60% of patients treated with Vabysmo could be treated every four months, compared with 45% in year one
New drug due for launch in Europe in the second quarter
Will pay $100m upfont and pledges $210m in milestone payments
Head-to-head trial with rival Eylea could boost sales
Novel alliance between two biotechs
Both sides claim to be acting in patients’ best interest
Next gen eye treatment offers less frequent dosing
Industry criticises judgement – fearful of ‘undermining regulation’ as well as big earning products
Bayer’s Eylea remains the drug to beat, however
But CEO Len Schleifer says there’s time to fix that
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology